HomeMedical

Medical

spot_imgspot_img

Exploring New Collaborative Opportunities! The Indonesia-China Healthcare and Biotech Investment Forum Successfully Held

On 27 July 2023, on the eve of the highly anticipated Chengdu FISU World University Games, the Minister of Health Indonesia Budi Gunadi Sadikin...

LAC FullCal and LAC Joint Protec: Stronger Bones and Healthier Joints for Pregnant/Postpartum Mothers

Gazing at the pregnancy test kit, as the faint double-lines slowly appear, can be an emotional rollercoaster of happiness and trepidation. Pregnancy is a beautiful journey, but it...

Peptomyc Announces the Approval of Its Phase 1b Trial Testing OMO-103 in Combination With Standard of Care in PDAC Patients

OMO-103 in Phase 1b clinical trial Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has...

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised...

BioGX Candida Auris PCR Assay Global Adoption Accelerates

BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready(TM) PCR assay* for detection of Candida auris,...

HanchorBio Announces Taiwan FDA IND Approval for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

HanchorBio Received IND Approval of HCB101 Multi-Regional Clinical Trial By Taiwan FDA HanchorBio Inc., a global clinical-stage biotechnology company developing innovative immuno-biomedicines, announced today...

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform

 RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img